Atom Investors LP Has $3.95 Million Stock Position in Encompass Health Co. (NYSE:EHC)

Atom Investors LP boosted its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 460.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,829 shares of the company's stock after acquiring an additional 33,544 shares during the period. Atom Investors LP's holdings in Encompass Health were worth $3,946,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of EHC. CIBC Asset Management Inc boosted its position in Encompass Health by 3.5% during the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company's stock valued at $286,000 after purchasing an additional 100 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in Encompass Health by 1.3% during the second quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company's stock worth $845,000 after buying an additional 123 shares in the last quarter. V Square Quantitative Management LLC grew its stake in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock valued at $39,000 after purchasing an additional 140 shares during the period. Verdence Capital Advisors LLC boosted its position in Encompass Health by 4.6% in the third quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company's stock valued at $355,000 after buying an additional 160 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC increased its stake in shares of Encompass Health by 6.6% in the second quarter. Mount Yale Investment Advisors LLC now owns 2,749 shares of the company's stock valued at $236,000 after buying an additional 170 shares in the last quarter. Institutional investors own 97.25% of the company's stock.

Encompass Health Trading Down 0.5 %

NYSE:EHC traded down $0.54 during mid-day trading on Monday, hitting $102.40. 519,698 shares of the company's stock were exchanged, compared to its average volume of 639,795. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health Co. has a fifty-two week low of $64.15 and a fifty-two week high of $104.55. The firm has a market capitalization of $10.32 billion, a P/E ratio of 24.71, a PEG ratio of 1.36 and a beta of 0.88. The company has a 50 day simple moving average of $98.16 and a 200-day simple moving average of $91.45.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 earnings per share. As a group, research analysts expect that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health's dividend payout ratio is presently 16.43%.

Analyst Upgrades and Downgrades

EHC has been the subject of a number of recent analyst reports. UBS Group upped their price objective on Encompass Health from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Barclays upped their price objective on Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a research note on Tuesday, October 29th. KeyCorp upped their price target on shares of Encompass Health from $115.00 to $117.00 and gave the company an "overweight" rating in a research note on Tuesday, October 29th. Stephens reiterated an "overweight" rating and issued a $105.00 price target on shares of Encompass Health in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada boosted their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.